诺和诺德公司股价因 CagriSema 减重效果未达预期下跌 8%
Novo Nordisk shares dropped 8% following disappointing Phase 3 trial results for its weight loss drug CagriSema, which showed only 15.7% weight loss in overweight adults with type 2 diabetes after 68 weeks, falling short of the expected 25%. The company plans to file for regulatory approval in Q1 2026. Despite the setback, Novo Nordisk remains committed to its weight loss portfolio and R&D efforts, according to executive vice president Martin Holst Lange.
Mar. 10, 2025 Novo Nordisk (NVO, Financial) shares fell 8% on Monday morning following disappointing Phase 3 trial results for its weight loss drug CagriSema. The Redefine 2 trial showed that CagriSema helped overweight adults with type 2 diabetes lose 15.7% of body weight after 68 weeks, compared to 3.1% with placebo. This outcome fell short of the company's previous forecast of 25% weight loss.
CagriSema is a once-weekly injection combining cagrilintide and semaglutide, the active ingredient in Novo Nordisk's successful drug Wegovy. The drugmaker expects to file for its first regulatory approval for CagriSema in the first quarter of 2026.
Novo Nordisk executive vice president for development, Martin Holst Lange, said, The REDEFINE 2 results confirmed the superior efficacy of CagriSema in patients with overweight or obesity and type 2 diabetes. We look forward to submitting this data to regulators to potentially bring this next-generation therapy to millions in need.
Despite the setback, Novo Nordisk remains committed to its weight loss portfolio and robust R&D efforts.
